We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA to Re-Inspect Andrx Plant Over GMP Problems; No Date Set
FDA to Re-Inspect Andrx Plant Over GMP Problems; No Date Set
December 15, 2005
The FDA plans to re-inspect Andrx’s manufacturing facility to resolve good manufacturing practice (GMP) concerns, but did not indicate when it would conduct the inspection, Andrx said in a Dec. 15 SEC filing.